Invasive candidiasis is an important fungal disease caused by Candida albicans and,
increasingly, non-albicans Candida pathogens. Invasive Candida infections originate most …

Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

Fungal endocarditis accounts for 1% to 3% of all infective endocarditis cases, is associated
with high morbidity and mortality (> 70%), and presents numerous challenges during clinical …

The objectives of this study were to assess Candida spp. distribution and antifungal
resistance of candidaemia across Europe. Isolates were collected as part of the third ECMM …

Disparities in social determinants of health (SDOH) play a significant role in causing health
inequities globally. The physical environment, including housing and workplace …

Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of
candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for …

Candida auris is an emerging, multidrug‐resistant yeast, causing outbreaks in healthcare
facilities. Echinocandins are the antifungal drugs of choice to treat candidiasis, as they …

Background Yet often overlooked in public health discourse, fungal infections pose a
crucialglobal disease burden associated with annual mortality rates approximately equal to …

Introduction Despite antifungal advancements, candidaemia still has a high mortality rate of
up to 40%. The ECMM Candida III study in Europe investigated the changing epidemiology …

Invasive candidiasis (IC) is an increasingly prevalent, costly, and potentially fatal infection
brought on by the opportunistic yeast, Candida. Previously, IC has predominantly been …